LCG
PRDS

Luxor Capital Group’s Pardes Biosciences, Inc. Common Stock PRDS Stock Holding History

Luxor Capital Group’s Portfolio PRDS Stock Details PRDS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-11,288
Closed -$112K – 179
2021
Q1 		$112K Buy
+11,288
New +$117K ﹤0.01% 147

Other funds holding PRDS

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Arena Capital Advisors Los Angeles, California $208M AUM 11.42% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
JCM
JS Capital Management New York $109M AUM 34.13% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SRCM
Sage Rock Capital Management New York $22.3M AUM 4.09% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
MAMNY
Marathon Asset Management (New York) New York $12M AUM 8.79% 1-Year Est. Return

Luxor Capital Group's PRDS Position: Q2 2021 in Review

Luxor Capital Group sold out of Pardes Biosciences, Inc. Common Stock (PRDS) in Q2 2021, closing a stake of 11,288 shares — an estimated $112K sold.

Luxor Capital Group first reported a position in PRDS in Q1 2021 and held it in 1 quarter. The position peaked at $112K in Q1 2021. 69 funds tracked by Wall St. Rank hold PRDS as of Q2 2021.

  • Luxor Capital Group reported no remaining Pardes Biosciences, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Luxor Capital Group sold 11,288 Pardes Biosciences, Inc. Common Stock shares in Q2 2021, an estimated $112K.
  • Luxor Capital Group first reported a position in Pardes Biosciences, Inc. Common Stock in Q1 2021 and held it in 1 quarter.
  • Luxor Capital Group's Pardes Biosciences, Inc. Common Stock position peaked at $112K in Q1 2021.
  • 69 funds tracked by Wall St. Rank held Pardes Biosciences, Inc. Common Stock as of Q2 2021.

Based on Luxor Capital Group's 13F filing for Q2 2021, filed 17 Aug 2021.